Below are our currently enrolling studies for patients with psoriatic arthritis.
Sponsor: Janssen
/assets/production/practices/c1f0c98a14a26efc3f61c530443c39569f27073b/images/2693130.jpg)
Sponsor: JanssenProtocol Number: CNTO1959PSA3005
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.
Detailed Information: Here
To learn more or see if you qualify: Click Here
/assets/docs/421578.png)
Sponsor: SunPharma
Protocol Number: TILD-19-19
This is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF naïve subjects with active PsA .
Detailed Information: Here
To learn more or see if you qualify: Click Here